Previous 10 | Next 10 |
Patent Opens Pathway to Disruptive Ischemia and Arrhythmia Detection Product in Multi-billion Dollar Wearables Device Market HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for...
HeartBeam, Inc. (BEAT) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Branislav Vajdic – Founder and Chief Executive Officer Jon Hunt – Chief Business Officer Rick Brounstein – Chief Financial Officer ...
The following slide deck was published by HeartBeam, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: HeartBeam, Inc. 2022 Q3 - Results - Earnings Call Presentation
Shares of micro-cap cardiac medical device company HeartBeam ( NASDAQ: BEAT ) declined 8.8% to $3.42 in Friday mid-day trading, after it reported a wider Q3 loss, a rise in expenses and a deterioration in its cash position. If the losses hold, BEAT stock would be on track ...
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its financial and operational updates for the third quarter; the quarter ended...
HeartBeam press release ( NASDAQ: BEAT ): Q3 GAAP EPS of -$0.44. Cash totaled $6.5 million as of September 30, 2022, compared to $13.2 million as of December 31, 2021. For further details see: HeartBeam GAAP EPS of -$0.44
HeartBeam AIMI™ Platform Technology for use in Diagnosing Heart Attacks Submitted to FDA for Clearance Company on Track for Initial FDA Submission of HeartBeam AIMIGo™, the Telehealth Solution, in Q4 2022 AIMIGo Technology Receives Two Additional Patents ...
More than two years after the novel coronavirus was first discovered in Wuhan, China, the infectious virus is still wreaking havoc among the global population. Although most countries, with the notable exception of China, have almost wholly loosened their tight pandemic policies, the res...
New research has found that smart watches can be used to detect atrial fibrillation accurately using an electrocardiogram application. Atrial fibrillation is an irregular heart rhythm that may cause blood clots. It also heightens an individual’s risk of heart failure and stroke, a...
HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced that it will hold a conference call at 4:30 p.m ET on Thursday, Nov. 10, 2022. HeartBeam CEO and Founder Branisl...
News, Short Squeeze, Breakout and More Instantly...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has been added to the Russell Microcap(R) Index. The move was effective after market close on June 28, 2024, and is part of FTSE Russell’s annual reconst...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap® Index effective after the market close on June 28, 2024 as part of FTSE Russell...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel o...